Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)-Reference-Cited by-同舟云学术

Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)

Published:2023-11 Issue:7 Volume:24 Page:e247-e253
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Asao Tetsuhiko^ORCID,Shukuya Takehito^ORCID,Mimori Tomoyasu,Goto Yasushi,Tanaka Hiroshi,Takayama Koichi,Tsubata Yukari,Tachihara Motoko,Suzuki Takuji,Kaira Kyoichi,Ko Ryo,Zenke Yoshitaka,Akamatsu Hiroaki,Tanizaki Junko,Ikeda Satoshi,Sugawara Shunichi,Mizutani Hideaki,Mori Keita,Takahashi Kazuhisa

Funder

Juntendo University

Chugai Pharmaceutical

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies;Engels;Int J Cancer,2003

2. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?;Marx;J Thorac Oncol,2022

3. Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database;Ruffini;J Thorac Oncol,2014

4. Thymic carcinoma outcomes and prognosis: results of an international analysis;Ahmad;J Thorac Cardiovasc Surg,2015

5. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan;Kondo;Ann Thorac Surg,2003

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas;Clinical Lung Cancer;2024-06